NCT05296525 - Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

April 22, 2024

Study Completion Date

April 22, 2024

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

GDA-201

NAM-expanded allogeneic NK cells

Trial Locations (6)

Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital, New York

Mayo Clinic Jacksonville, Jacksonville

Henry Ford Medical Center, Detroit

Regents of the University of Minnesota, Minneapolis

Loyola University, Cardinal Bernardin Cancer Center, Maywood

Dana-Farber/Mass General Brigham Cancer Care, Inc., Boston